Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01055678

To Evaluate the Characteristics of a Breast Cancer

Pilot Study to Characterize the HRHV Axis in the Microenvironment of Breast Cancers

Status
Withdrawn
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Mark Dewhirst · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this pilot study is to determine the prevalence of markers of chronic and cycling hypoxia and reactive species stress (oxidative and nitrosative) in the breast cancer tumor microenvironment. The study is based around four cornerstone features of the pathologic microenvironment - Hypoxia, Reactive Species (reactive oxygen and nitrogen species), HIF-1 and VEGF, which we term the HRHV axis. Fifty breast cancer patients with planned surgical excision will be administered the hypoxia marker drug, EF5, 24-36 hr prior to surgical excision. EF5 is a non-therapeutic drug and provides no direct benefit to those patients enrolled in this pilot study. Tissues obtained intra-operatively will be snap frozen and subsequently analyzed for EF5 binding. Immunohistochemical analysis of a cohort of immunohistochemical and urine markers that depict the HRHV axis will be examined. The association of the markers with the presence of hypoxia, as determined by EF5 positivity, will be determined. Data from this pilot study will be used to establish the prevalence of markers of the HRHV axis in breast cancer. This information will be crucial for future human trials in which the HRHV axis is therapeutically targeted.

Conditions

Interventions

TypeNameDescription
DRUGEF5An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
PROCEDUREPartial or Total MastectomyA small tissue sample will be removed from the excised tissue and will be stored for later analysis.

Timeline

Start date
2010-01-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2010-01-26
Last updated
2012-12-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01055678. Inclusion in this directory is not an endorsement.